

eISBN: 978-1-68108-363-6
ISBN: 978-1-68108-364-3

eISSN: 2468-7383
ISSN: 2468-7375

CURRENT TECHNOLOGIES TO INCREASE THE TRANSDERMAL DELIVERY OF DRUGS

VOLUME 2

*PHYSICAL PENETRATION ENHANCERS:
THERAPEUTIC APPLICATIONS AND DEVICES*

Editor:
José Juan Escobar-Chávez

Bentham  Books

**Current Technologies to
Increase the Transdermal
Delivery of Drugs
(Volume 2)**

***Physical Penetration Enhancers:
Therapeutic Applications and
Devices***

Edited by

José Juan Escobar-Chávez

Universidad Nacional Autónoma de México

Facultad de Estudios Superiores Cuautitlán

Unidad de Investigación Multidisciplinaria

*Laboratorio 12: Sistemas transdérmicos y materiales
nanoestructurados*

Av. Cuautitlán-Teoloyucan. San Sebastián Xhala

Cuautitlán Izcalli, Estado de México. C.P 54714 México

Current Technologies to Increase the Transdermal Delivery of Drugs

Volume # 2

Physical Penetration Enhancers: Therapeutic Applications and Devices

Editor: José Juan Escobar-Chávez

eISSN (Online): 2468-7383

ISSN (Print): 2468-7375

eISBN (Online): 978-1-68108-363-6

ISBN (Print): 978-1-68108-364-3

©2016 Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

FOREWORD	i
SPECIAL ACKNOWLEDGEMENTS	iii
PREFACE	iv
LIST OF CONTRIBUTORS	vi
CHAPTER 1 PHYSICAL PENETRATION ENHANCERS: AN OVERVIEW	3
<i>Isabel Marlen Rodríguez-Cruz, Clara Luisa Domínguez-Delgado, José Juan Escobar-Chávez, Miriam López-Cervantes cpf Roberto Díaz-Torres</i>	
1. INTRODUCTION	4
2. PHYSICAL ENHANCERS	5
2.1. General Aspects of Physical Enhancers	5
2.2. Classification	7
2.2.1. Sonophoresis	7
2.2.2. Iontophoresis	8
2.2.3. Electroporation	8
2.2.4. Microneedles (MNs)	9
2.2.5. Radiofrequency	9
2.3. Therapeutic Applications	10
3. NANOCARRIER SYSTEMS	12
3.1. General Aspects of Nanocarrier Systems	12
3.2. Biodistribution of Nanocarrier Systems	13
3.3. Toxicity of Nanocarrier System	14
4. IMPORTANCE OF USING NANOCARRIER SYSTEMS WITH PHYSICAL ENHANCERS AND THERAPEUTIC APPLICATIONS	14
5. OVERALL COSTS	21
CONCLUSION	22
CONFLICT OF INTEREST	22
ACKNOWLEDGEMENTS	22
REFERENCES	22
CHAPTER 2 IONTOPHORESIS	35
<i>María Aracely Calatayud-Pascual, Cristina Balaguer-Fernández, Alicia López-Castellano cpf Virginia Merino</i>	
1. INTRODUCTION	35
2. MECHANISM OF ACTION AND THEORETICAL BASIS OF IONTOPHORESIS	37
3. FACTORS INFLUENCING IONTOPHORETIC TRANSPORT	40
4. REVERSE IONTOPHORESIS	43
5. THERAPEUTICAL APPLICATIONS OF IONTOPHORESIS	44
5.1. Iontophoresis for Topical Delivery	44
5.1.1. Corticosteroids	44
5.1.2. Anaesthetics	44
5.1.3. Hyperhidrosis	45
5.1.4. Diagnosis	46
5.1.5. Dentistry	46
5.1.6. Treatment of Nail Diseases	47
5.1.7. Antineoplastic Drugs	48
5.1.8. Proteins	50

5.1.9. Ophthalmic Applications	50
5.1.10. Iontophoresis for Systemic Delivery	51
5.1.11. Reverse Iontophoresis	53
6. IONTOPHORETIC DEVICES	54
CONCLUSION	56
CONFLICT OF INTEREST	57
ACKNOWLEDGEMENTS	57
REFERENCES	57
CHAPTER 3 DELIVERY OF DNA-BASED VACCINES WITH IN VIVO ELECTROPORATION	68
<i>Trevor RF Smith, Katherine Schultheis cfp Kate E Broderick</i>	
1. INTRODUCTION	68
1.1. DNA-based Vaccination: The Concept	69
1.2. DNA-based Vaccination: The Early Years	69
1.3. DNA-based Vaccination: The Delivery	70
2. MECHANISM OF PDNA TRANSFER BY ELECTROPORATION	72
3. ELECTROPORATION DEVICES FOR THE IN VIVO DELIVERY OF DNA-BASED VACCINES	73
4. THE SAFETY AND TOLERABILITY OF DNA-BASED VACCINATION COMBINED WITH ELECTROPORATION	83
5. ELECTROPORATION AUGMENTS THE IMMUNE RESPONSE	84
6. ELECTROPORATION-ENHANCED DNA-BASED VACCINE DELIVERY IN THE CLINIC	86
6.1. Cancer Immunotherapy	86
6.2. Infectious Disease Prophylaxis and Immunotherapy	89
7. FUTURE PROSPECTS AND CHALLENGES	91
CONFLICT OF INTEREST	92
ACKNOWLEDGEMENTS	92
REFERENCES	92
CHAPTER 4 SONOPHORESIS: THERAPEUTICAL USES AND DEVICES	101
<i>José Juan Escobar-Chávez, Pablo Serrano Castañeda, Omar Rodrigo -Guadarrama-Escobar, Alma Lidia Aguiñaga-Mireles, Miriam López Cervantes, Clara Luisa Domínguez-Delgado cfp Jessica Martínez-Hernández</i>	
1. INTRODUCTION	101
2. THE US	103
3. ADVANTAGES AND DISADVANTAGES OF SONOPHORESIS	104
4. ULTRASOUND THERAPEUTICAL APPLICATIONS	106
4.1. Drug Delivery	106
4.1.1. Topical/Transdermal Drug Delivery	106
4.1.2. Ocular Drug Delivery	106
4.1.3. Application in Nail by US	114
4.2. Gene Delivery	114
4.3. Sports Medicine	116
5. SONOPHORETIC DEVICES	116
5.1. Sonophoretic Systems Available in the Market	117
5.1.1. Patch-Cap™, U-strip™, U-Wand™ and A-Wand™ Devices	117
5.1.2. Sonoderm Technology	119
5.1.3. SonoLysis	119
5.1.4. ClotBust-ERTM	121
5.1.5. EkoSonic® Endovascular System, EkoSonic® Endovascular System with MACH4e and EkoSonic® SV (Small Vessel) Endovascular System	122
5.1.6. SonoPrep® Skin Permeation System	124
6. COMBINATION OF SONOPHORETIC SYSTEMS WITH OTHER ENHANCING TECHNOLOGIES	126
6.1. US and Chemical Penetration Enhancers	126

6.2. US and Iontophoresis	127
6.3. US and Microneedles	128
6.4. US and Nanocarriers Systems	130
CONCLUSION	131
CONFLICT OF INTEREST	131
ACKNOWLEDGEMENTS	132
REFERENCES	132

CHAPTER 5 RADIOFREQUENCY AS PHYSICAL APPROACH FOR TRANSDERMAL PENETRATION ENHANCEMENT, NON-SURGICAL SKIN PROCEDURES, ORTHOPEDICS AND CHRONIC PAIN 150

Jennyfer Cázares Delgadillo

1. INTRODUCTION	150
2. DEFINITION AND THEORETICAL BASIS	153
3. MECHANISM OF ACTION	154
3.1. RF Waveforms and Power Modes	156
3.1.1. <i>Monopolar Mode</i>	157
3.1.2. <i>Unipolar Mode</i>	157
3.1.3. <i>Bipolar Mode</i>	157
3.2. RF Tissue Effects	157
4. THERAPEUTIC APPLICATIONS	159
4.1. Transdermal Drug Delivery	159
4.2. Cutaneous Gene Therapy	168
4.3. Non-Surgical Dermatologic Treatments	174
4.3.1. <i>Acne and Scars</i>	174
4.3.2. <i>Hyperhidrosis</i>	177
4.3.3. <i>Skin Tightening</i>	178
4.3.4. <i>Reduction of Adipose Tissue Volume</i>	180
4.3.5. <i>Melasma</i>	184
4.4. Orthopedic Treatments	184
4.5. Chronic Pain Treatments	186
5. DEVICES	187
5.1. Transdermal RF Drug Delivery Systems	187
5.2. Non-invasive RF Systems Used in Skin Procedures	190
5.3. Non-invasive RF Technology Associated to Other Energy Modalities	193
6. COST, RISKS AND SAFETY IN THE USE OF NON-INVASIVE RF TREATMENTS	194
CONCLUSION	197
CONFLICT OF INTEREST	198
ACKNOWLEDGEMENTS	198
REFERENCES	198

CHAPTER 6 MICRONEEDLES

Yunhua Gao, Yuqin Qiu and Suohui Zhang

1. INTRODUCTION	210
2. DEFINITION OF MICRONEEDLES	211
3. MECHANISMS OF ACTION	213
4. THERAPEUTIC APPLICATIONS	218
4.1. Drug Delivery	223
4.1.1. <i>Insulin & Insulin Analogs</i>	223
4.1.2. <i>Parathyroid Hormone (PTH)</i>	224
4.1.3. <i>Lidocaine & Other Local Anesthetics</i>	225
4.1.4. <i>Naltrexone & 6-β-Naltrexol</i>	227
4.1.5. <i>Retinoic Acid, Retinyl Retinoate & Ascorbic Acid</i>	228

4.2. Physiotherapy	229
4.3. Miscellaneous Application	230
4.4. Vaccination	231
4.4.1. Mechanism of Action	231
4.4.2. Vaccine Platforms	232
4.4.3. Influenza Vaccine	232
4.4.4. Other Vaccines	234
5. COMBINATION OF MICRONEEDLE WITH ELECTRICALLY DRIVEN TECHNOLOGIES	237
5.1. Microneedle and Iontophoresis	237
5.2. Microneedle and Sonophoresis	239
5.3. Microneedle and Electroporation	240
6. DEVICES IN RESEARCH OR IN THE MARKET	241
CONCLUSIONS	243
CONFLICT OF INTEREST	244
ACKNOWLEDGEMENTS	244
REFERENCES	244
CHAPTER 7 NANOCARRIER SYSTEMS WITH THE USE OF PHYSICAL ENHANCERS	260
<i>Roberto Diaz-Torres, Isabel Marlen Rodríguez-Cruz, Elizabeth García-García, Clara Luisa</i>	
<i>Dominguez-Delgado cpf Patricia Ramirez-Noguera</i>	
1. INTRODUCTION	261
2. DEFINITION AND GENERALITIES OF NANOCARRIER SYSTEMS	262
3. CLASSIFICATION OF NANOCARRIERS	268
3.1. Liposomes	271
3.2. Lipospheres	274
3.3. Dendrimers	275
3.4. Nanoparticles	277
3.4.1. Solid Lipid Nanoparticles (SLN)	280
3.4.2. Magnetic Nanoparticles (MNPs)	280
3.4.3. Gold Nanoparticles (GNPs)	280
3.5. Nanoemulsions	281
3.6. Micelles	281
3.7. Niosomes	282
3.8. Transfersomes (TF)	282
3.9. Quantum Dots (QDs)	282
3.10. Aquasomes	283
3.11. Nanotoxicology	283
4. PHYSICAL ENHANCERS	284
4.1. Ultrasound	284
4.2. Iontophoresis	286
4.3. Microneedles	288
5. PHYSICAL ENHANCERS IN COMBINATION WITH THE USE OF NANOCARRIERS	290
5.1. Microneedles and Nanocarriers	290
5.2. Iontophoresis and Nanocarriers	293
5.3. Ultrasound and Nanocarriers	295
6. PHYSICAL ENHANCERS AND NANOPARTICLES DEVICES	298
6.1. Microneedles Devices	298
6.2. Iontophoretic Devices	299
6.3. Ultrasound Devices	300
CONCLUSION	301
CONFLICT OF INTEREST	301
ACKNOWLEDGEMENTS	301
REFERENCES	301
GLOSSARY	315
SUBJECT INDEX	316

FOREWORD

Pharmaceutical knowledge has grown exponentially over the last 40 years. We now have a much clearer understanding of how drugs are absorbed into, distributed within, and cleared from the body.

The potency of agents with which we deal continues to increase, and our ability to unravel mechanisms of action proceeds. New drugs –in particular peptides, proteins and other biological response modifiers- are being developed and new challenges await pharmaceutical scientists. Controlled drug delivery represents a field that must keep pace with changing nature of chemotherapy. Tighter control of drug input into the body in both quantitative and temporal senses is crucial, and design of *new delivery systems* must respond to this demand for increased sophistication. For this purpose, scientists have used new technologies to improve the penetration rate of drugs. These technologies include physical and electrical methods that include iontophoresis (small direct current), sonophoresis (mainly by low frequency ultrasound energy), electroporation (by application of short micro to milli-second electrical pulses), radiofrequency (laser-generated stress), microneedles and also the use of nanocarriers alone or in combination with the use of the above mentioned physical enhancers. These biophysical techniques have many others therapeutical applications that include physiotherapy, gene delivery, DNA based vaccination, drug administration, diagnosis, dentistry, *etc.*

The development of technology has permitted the generation of devices that involve the use of physical enhancers for many of the mentioned therapeutical applications.

The objective of this book is to provide a general and an updated overview of the theoretical and practical aspects of iontophoresis, electroporation, sonophoresis, microneedles, radiofrequency and transdermal nanocarrier systems on the delivery of transdermal drugs. Such a generalized approach would be helpful in medicine, pharmacy, drug discovery, drug delivery, drug design and toxicological research.

The contributors to this text have been directed to emphasize updates on above mentioned technologies involved in therapeutic applications and devices. Authors were selected for their knowledge and reputation in their subject area, and for their ability to address objectively the topics of this book. I believe that they have performed this task effectively, producing a text

ii

that will facilitate and optimize future developmental programs in pharmacy, medicine and pharmaceutical technology.

Dr. Amparo Nácher Alonso
Department of Pharmacy and Pharmaceutical Technology
University of Valencia,
Spain

SPECIAL ACKNOWLEDGEMENTS

- **PAPIIT IT 200115**, PAPIIT IT 200115: “Diseño, desarrollo y caracterización de microagujas poliméricas biodegradables y geles termorreversibles cargados de sustancias de interés terapéutico para el tratamiento de enfermedades como alternativas a la vía oral”.
- **PAPIME 200414**: Diseño y Desarrollo de Prácticas Experimentales para la Elaboración del Manual de la Asignatura de Análisis de Medicamentos de la Carrera de Licenciatura en Farmacia de la FES Cuautitlán.
- **Cátedra PIAPIC**: Desarrollo de Formas Farmacéuticas No Convencionales para la Administración de Fármacos.

PREFACE

“Physical penetration enhancers: Therapeutic applications and devices”, is the second volume of the series *“Current technologies to increase the transdermal delivery of drugs”* from Bentham Science Publishers. This book provides an overview of main current physical enhancers in the therapeutical and pharmacy field. The importance of therapeutical applications of physical enhancers, and devices existing in the market will be addressed in each chapter. Exclusive chapters on Iontophoresis, Sonophoresis, Electroporation, Microneedles, Radiofrequency and more recently the use of nanoparticles in combination with the above mentioned physical enhancers, highlighting their main therapeutic applications will be included in this book.

Currently, there are no unique books available on therapeutical applications of physical penetration enhancers and currently devices in the market. Brief chapters and books describing only one of the physical enhancers or only one of the therapeutical applications (*i.e.*, transdermal drug delivery) of these enhancers are available to readers in some drug delivery or toxicology books. For these reasons, more detailed information about therapeutical applications (drug delivery, gene therapy, physiotherapy, skin disorders, vaccination, *etc.*) is now needed. This book presents a general overview of the theoretical and therapeutic aspects of iontophoresis, electroporation, sonophoresis, microneedles, radiofrequency and nanocarriers systems in combination with physical enhancers. Such a generalized approach would be helpful in medicine, pharmacy, drug discovery, drug delivery and toxicological research.

A comprehensive book which provides the basis and updated therapeutical research information is necessary. For this fact, this e-book will be an interesting option that could be used by students and academics of medicine, biopharmacy, pharmaceutical technology, design and development of drugs, pharmacology, by physicians, dermatologists, scientists and pharmaceutical R & Ds. The book also will be useful for medicine, pharmacy, pharmacology and pharmaceutical technology departments of different Universities all over the world.

In summary, this e-book reviews the therapeutical uses of physical enhancers such as iontophoresis, sonophoresis, electroporation, microneedles, radiofrequency and nanocarriers in combination with physical enhancers. After an introduction, definition, mechanisms of

action, the focus turns to the relevance of therapeutical applications studies and finally the different physical enhancer devices in the market.

Dr. José Juan Escobar-Chávez

Universidad Nacional Autónoma de México
Facultad de Estudios Superiores Cuautitlán
Unidad de Investigación Multidisciplinaria
Laboratorio 12: Sistemas transdérmicos y materiales nanoestructurados
Av. Cuautitlán-Teoloyucan. San Sebastián Xhala
Cuautitlán Izcalli, Estado de México. C.P 54714,
México

List of Contributors

- Alicia López Castellanos** Instituto de Ciencias Biomédicas. Departamento de Farmacia, Facultad de Ciencias de la Salud. Universidad CEU Cardenal Herrera, 46113, Moncada, Spain
- Alma Lidia Aguiñaga Mirelles** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
- Clara Luisa Domínguez-Delgado** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
- Cristina Balaguer-Fernández** Instituto de Ciencias Biomédicas, Departamento de Farmacia. Facultad de Ciencias de la Salud. Universidad CEU Cardenal Herrera, 46113 Moncada, Spain
- Elizabeth García-García** Psicofarma S.A. de C.V., Calz. de Tlalpan 4369, Col, Toriello Guerra, Distrito Federal. C.P.14050, México
- Isabel Marlen Rodríguez-Cruz** Hospital Regional de Alta Especialidad Zumpango. Unidad de Enseñanza e Investigación, Carretera Zumpango-Jilotzingo #400. Barrio de Santiago 2da Sección. Zumpango,, Estado de México. C.P. 55600, México
- Jennyfer Cázares Delgadillo** R&I, L’Oreal, 188-200 rue Paul-Hochart, 94550 Chevilly-Larue, France
- José Juan Escobar-Chávez** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
- Kate Broderick** Inovio Pharmaceuticals, Inc., 660W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA
- Katherine Schultheis** Inovio Pharmaceuticals, Inc., 660W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA
- María Araceli Catalayud-Pascual** Instituto de Ciencias Biomédicas. Departamento de Farmacia, Facultad de Ciencias de la Salud. Universidad CEU Cardenal Herrera, 46113 Moncada, Spain

- Miriam López-Cervantes** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
Laboratorio de Farmacotecnia. Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Villa Quietud, Coyoacán, Distrito Federal,, México, C.P. 04960, México
- Omar Rodrigo Guadarrama-Escobar** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
- Pablo Serrano Castañeda** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México
- Patricia Ramírez Noguera** Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México,, Estado de México, México
- Roberto Díaz-Torres** Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México,, Estado de México, México
- Suohui Zhang** Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
- Trevor R.F. Smith** Inovio Pharmaceuticals, Inc., 660W, Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA,
- Virginia Merino** Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia. Departament de Farmàcia i Tecnologia Farmacèutica, Facultat de Farmàcia, Universitat de València, 46100 Burjassot, Spain
- Yunhua Gao** Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
- Yuqin Qiu** Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China

To my Family and all my personal affections.

Physical Penetration Enhancers: An Overview

Isabel Marlen Rodríguez-Cruz^{1,2,*}, Clara Luisa Domínguez-Delgado³, José Juan Escobar-Chávez³, Miriam López-Cervantes^{3,4} and Roberto Díaz-Torres⁵

¹ Hospital Regional de Alta Especialidad Zumpango. Unidad de Enseñanza e Investigación. Carretera Zumpango-Jilotzingo #400. Barrio de Santiago 2da Sección. Zumpango, Estado de México. C.P. 55600, México

² Laboratorio de Investigación en Citogenética Básica del CBT Dr. Alfonso León de Garay. Calle Fresnos S/N, San Mateo, Tequixquiac, Estado de México C.P.55657, México

³ Unidad de Investigación Multidisciplinaria. Laboratorio 12: "Sistemas Transdérmicos y Nanomateriales". Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán-Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México CP. 54714, México

⁴ Laboratorio de Farmacotecnia. Universidad Autónoma Metropolitana-Xochimilco. Calzada del Hueso 1100, Villa Quietud, Coyoacán, Distrito Federal, México, C.P. 04960, México

⁵ Unidad de Investigación Multidisciplinaria. Laboratorio 9: "Toxicología y genética". Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México, México

Abstract: A number of physical methods for drug penetration enhancement and improve bioavailability of the stratum corneum (SC) such as micro-needles, heating, iontophoresis, electroporation, and ultrasound have also been evaluated in the last decade. On the other hand, nanotechnology has shown remarkable potential in target-specific delivery of drugs in the body. In this chapter, we discuss the role of overview about nanocarrier systems, physical enhancers and their possible combination in order to improve the passage of molecules through the organ systems. All these methods have their own advantages and disadvantages, nevertheless, novel developments are projected to be more adaptable to different needs.

* **Corresponding author Isabel Marlen Rodríguez-Cruz:** Hospital Regional de Alta Especialidad de Zumpango. Unidad de Enseñanza e Investigación, Zumpango, Estado de México. C.P.56600, México; & Laboratorio de Investigación en Citogenética Básica del CBT Dr. Alfonso León de Garay. Calle Fresnos S/N, San Mateo, Tequixquiac, Estado de México C.P.55657, México; Tel: +52 5513428688; E-mail: isabelmarlen@yahoo.com.mx

José Juan Escobar-Chávez (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

Keywords: Controlled release, Drug delivery, Nanocarrier systems, Nanomedicine, Nanoparticles, Nanopharmaceutics, Physical penetration enhancers, Synergism, Therapeutic applications.

1. INTRODUCTION

In order to improve the penetration ability of agents therapeutics into systemic circulation, numerous methodologies have been investigated, developed and patented such as physical enhancers: iontophoresis, electroporation, ultrasound, microneedles and radiofrequency [1 - 10]. Alternatively, nanocarrier systems are being used as drug transporter systems. In this review, the expression nanocarrier referred to nano-systems that are used for effective carriage of loaded drug to the target sites or cells such as nanoparticles (NP), nanoemulsions, nanosuspensions, liposomes, micelles, vesicles, dendrimers and transfersomes. In the case of NP, these are defined as nanospheres or nanocapsules which is different in the morphology and architecture. Nanospheres are prepared by a polymeric matrix and nanocapsules are made of an oil core delimited by a polymeric membrane [1].

Currently, in order to improve penetration of nanocarrier systems into organ systems, especially to increase the skin permeability of drugs, a number of methods have been developed including use of physical enhancers [10 - 15]. Particularly, the skin has become an important way of administration of therapeutics agents for dermal and transdermal drug delivery. Dermal and transdermal ways offer a viable non-invasive administration of drugs, and avoids the hepatic first-pass effect. Also, dermic drug delivery system localizes high concentrations of agent therapeutic at the site of action and consequently, decreasing the side effects [1].

Transdermal delivery involves increasing the penetration of a drug through the skin when a systemic effect is wanted. Though, the dermal and transdermal administration of drugs is influenced by on drug's physicochemical properties, for example, charge, solubility, diffusivity, molecular size, polarity and molecular weight [1]. This chapter reviews the combination of nanocarrier systems and physical enhancers in order to improve the delivery of therapeutic molecules in many ways. Additionally, potential therapeutically applications of these physical

enhancers are reviewed in this chapter.

2. PHYSICAL ENHANCERS

2.1. General Aspects of Physical Enhancers

An enhancer is a technique that modify the penetration facility of drug chemically or physically. With the intention of increase the penetration ability of drugs into organ systems, numerous methodologies such as physical enhancers have been investigated, developed and patented (*e.g.* iontophoresis, electroporation, ultrasound, microneedles and radiofrequency) [4]. Tabel 1 shows the principal characteristics of these techniques.

Table 1. Physical enhancers.

Physical Enhancers	Definition	Characteristics	Refs
Sonophoresis	Sonophoresis is the application of ultrasonic energy that temporarily improves skin permeability.	Sonophoresis functions at frequencies of 20 kHz-16 MHz and intensities up to 14 W/cm ² (spatial average pulse average intensity, ISAPA) to enhance skin permeability.	[7]
Iontophoresis	Iontophoresis is the use of slight electric current in order to improve the transport of drugs, which consists of an anode and a cathode deposited on a surface (<i>e.g.</i> skin).	Iontophoresis uses an electric current of ~ 0.5 A/cm). A drug can pass through the surface by electromigration, electroosmosis or passive diffusion.	[8]
Electroporation	The electroporation technique consists of the application of a high electrical field pulses with the purpose to create nano-sized pores in a cell membrane and thus, increase the passage of ions and macromolecules through the skin.	Electroporation can be reversible and irreversible.	[4, 5]
Microneedles	Microneedles are used to open holes into the skin to create a pathway for the following delivery of drugs.	Generally, microneedles have a length of 100-500 μm.	[4, 5]
Radiofrequency	Radiofrequency ablation (RF) is a simple, safe, and effective therapy for chronic radiation proctopathy.	The frequency is between 10 kHz and 900 MHz.	[9]

According to physical enhancers, one of the main routes of drug administration is

Iontophoresis

María Aracely Calatayud-Pascual¹, Cristina Balaguer-Fernández¹, Alicia López-Castellano¹ and Virginia Merino^{2,*}

¹ Instituto de Ciencias Biomédicas. Departamento de Farmacia. Facultad de Ciencias de la Salud. Universidad CEU Cardenal Herrera, 46113 Moncada, Spain

² Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia. Departament de Farmàcia i Tecnologia Farmacèutica i Parasitologia, Facultat de Farmàcia, Universitat de València, 46100 Burjassot, Spain

Abstract: Transdermal administration offers an interesting alternative to oral and parenteral drug administration; nevertheless, skin is an important barrier for drug absorption. Iontophoresis, a technique that consists of the application of low current density across a membrane can facilitate drug entrance through it. Iontophoresis can be used for local effects on skin, nail, eye or ear and it can also be used for systemic delivery when applied through skin. In this chapter, the mechanisms involved in drug transport during iontophoresis application and factors affecting its efficacy are reviewed. Examples of the use of iontophoresis in different fields are presented together with the most recent research.

Keywords: Ear permeation, Electric current treatment, Electromotive drug delivery, Eye permeation, Iontophoresis, Iontophoretic devices, Low current treatment, Nail permeation, Physical permeation enhancement, Transdermal absorption.

1. INTRODUCTION

Epithelia general properties limit passive delivery of most compounds across

* **Corresponding author Virginia Merino:** Departament de Farmàcia i Tecnologia Farmacèutica i Parasitologia, Facultat de Farmàcia, Vicente Andrés Estellés sn, 46100 Burjassot, Spain; Tel: +34963543324; Fax: +34963544911; E-mail: merinov@uv.es

them. To overcome this barrier limitation several passive and active strategies have been attempted to ensure safe delivery and to improve efficacy of drugs as well as patient compliance.

Passive procedures, as optimization of formulation or drug carrying vehicles to increase permeability, in general do not greatly enhance the drug permeation of molecules with molecular weights higher than 500 Daltons. Active methods such as sonophoresis, iontophoresis, electroporation and other techniques such as laser microporation and microneedles produce superior enhancement of drug transport through the membranes. These methods, physically or mechanically, facilitate the delivery of various lipophilicities and molecular weights drugs, including proteins, peptides, and oligonucleotides [1, 2].

Among the methodologies mentioned, iontophoresis is one of the best-known and represents a promising physical penetration method to enhance delivery of drugs, especially through skin.

The application of low density electrical current, and voltage, through a membrane, called iontophoresis, promotes permeation of a therapeutic drug placed on the surface of the membrane.

Iontophoretic drug delivery through the skin offers several important advantages over more traditional dosage forms. First pass metabolism is avoided with iontophoretic transdermal administration and this technique usually increases patient compliance. Along with these advantages, iontophoresis provides additional ones:

- Delivery of both ionized and unionized polar drugs, that can have either low or high molecular weight.
- Continuous or pulsatile delivery of a drug can be selected, depending on the mode of current used.
- Permits ease ending of drug administration.
- Current mode, duration of the process and area of application, parameters that determine the amount of drug delivered, can be modified according to the needs.
- Easy skin recovery after application, since no severe irritation is produced.

- It can be used for systemic or local (topical) delivery of drugs.
- Inter and intra subject variability is considerably reduced compared with passive diffusion, since the rate of drug delivery is more dependent on applied current than on membrane characteristics.

Iontophoresis has been established as a safe, versatile and efficient enhancement technique and several iontophoretic devices have been marketed. Clinically, iontophoresis has been employed to deliver through skin fentanyl and lidocaine for pain relief [3, 4], pilocarpine to induce sweating (as a diagnostic test) [5], and tap water to treat hyperhidrosis [6]. Iontophoresis even has been used as a monitoring technique in diabetic patients, since it can be used to extract glucose from the skin [7]. Also, recently has seen an interest into the potential use of iontophoresis to deliver drugs through other membranes such as the nail and through the sclera and cornea, the two main barriers to eye drug delivery [8].

In this chapter basic concepts of iontophoresis will be discussed, examples of application of this delivery technique for drug application will be explained and currently existing iontophoretic devices for different treatments will be exposed.

2. MECHANISM OF ACTION AND THEORETICAL BASIS OF IONTOPHORESIS

During iontophoresis low density, and low voltage, current (less than $0.5 \text{ mA}\cdot\text{cm}^{-2}$, 1-10 V) is applied through an electrical circuit which electrodes are placed on a membrane surface. This allows the propelled ions to pass through the membrane.

In the course of current application skin resistance is reduced. It may be due to micro- or nano-pores formation as a consequence of proteins and lipids, present in the stratum corneum, reorientation under the application of the electric field; or it may be caused by the ions flux into stratum corneum (either from beneath the stratum corneum or from the formulation on it). Local changes can also take place in hair follicles and sweat glands. As a result the originated pores, negatives in charge considering the permselectivity of skin at physiological pH, may have different diameters and structures. Nevertheless, after current cessation skin resistance is recovered so it can be considered that skin alterations under iontophoresis are reversible [9].

Delivery of DNA-Based Vaccines with *In Vivo* Electroporation

Trevor R.F. Smith*, Katherine Schultheis and Kate E. Broderick

Inovio Pharmaceuticals, Inc., 660W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA

Abstract: Recent technological advances have re-established the value of DNA-based vaccines in tackling unmet medical needs. Such advances include the optimization of DNA plasmid constructs, the addition of novel molecular adjuvants into the formulations, and the development of *in vivo* delivery strategies such as electroporation (EP). The combination of DNA-based vaccines with the delivery platform of EP has enhanced the antigen expression by up to 1000-fold higher than DNA injection alone, resulting in greatly enhanced immunogenicity of DNA-based vaccines. Pre-clinical EP-enhanced DNA-based vaccination has elicited robust functional host immune responses to a myriad of disease targets resulting in protection from viral challenge or tumor growth, depending on the disease model. Significantly, the problems encountered in translating these responses to the clinic have been overcome, and equally impressive immune responses are being observed in human beings when DNA-based vaccination is married with EP, as was observed in a recent clinical trial. In this review we will cover the principles of EP in respect to enhancing DNA-based vaccination protocols targeting pDNA delivery to the muscle or skin, and discuss the top line results that have revealed for the first time clinical efficacy of DNA-based vaccine candidates.

Keywords: DNA-based vaccines, Electroporation.

1. INTRODUCTION

Thirty years ago Neumann *et al.* reported on the successful delivery of genes into

* Corresponding author Trevor R.F. Smith: Inovio Pharmaceuticals, Inc., 660W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, USA; E-mail: TSmith@inovio.com

cells in culture through the use of an electrical pulsing method [1]. This technique of gene delivery became known as electrotransfer or electroporation, and was quickly adapted to *in vivo* protocols to aide in the delivery of macromolecules, such as chemotherapeutics and plasmid DNA (pDNA), across the mammalian membrane of cells residing in a tissue rather than a culture dish. EP has been used in the clinic to efficiently deliver large molecule chemotherapeutics such as bleomycin in electrochemotherapy (ECT) [2], or high voltage irreversible EP (IRE) has proved efficacious at causing cancer cell death [3]. ECT and IRE have been reviewed in depth elsewhere [2, 3]. More recently, EP has been utilized to transfer nucleic acid constructs in gene therapy trials [4]. In this review we will focus on the use of EP to enhance the delivery of pDNA to elicit robust immune responses in DNA-based vaccination protocols.

1.1. DNA-based Vaccination: The Concept

Conceptually and experimentally, DNA-based vaccination is a very attractive platform. The vaccine construct is not an inactivated or attenuated version of a pathogen, or a pathogen-associated protein. The construct is designed to be a blue print of the antigen(s) of choice, which following nuclear delivery can be read by the host's own machinery, initiating its manufacture, processing and presentation. The major advantage of DNA-based vaccines over inactivated virus or viral protein-based vaccines is their ability to drive the generation of both T cell and B cell responses. This in conjunction with ease and speed of design and manufacture [5], and the stability of pDNA at room temperature, are some of the favorable traits associated with this technology [6]. Additionally, modern day genomics allows for customization of the vaccine, so scientists can marry molecular biology techniques with their understanding of the immune system to develop vaccines that encode novel antigens and/or combinations of antigens. DNA-based vaccination has the potential to harness the power of the immune system to tackle multiple unmet medical needs, such as HIV, RSV, Influenza, and various cancers.

1.2. DNA-based Vaccination: The Early Years

The first DNA-based vaccination studies were reported in the early 1990's, when multiple groups demonstrated the induction of immune responses following naked

injection of pDNA into mouse muscle [7 - 9]. It was demonstrated that *in vivo* transfection of mouse muscle cells with pDNA encoding target infectious agent-associated antigens could drive robust T cell and antibody responses against the pathogens, and importantly protect against future challenge. For example, Ulmer *et al.* reported that *in vivo* transfection with pDNA encoding influenza A nucleoprotein raised a protective immune response against subsequent challenge with a heterologous strain of influenza A virus in mice [9]. Such studies demonstrated that vaccination of small animals with naked pDNA could protect against infectious agents or halt tumorigenic growth [9, 10].

However, historical attempts in the 1990's to translate these pDNA vaccine successes into large animal models or humans ended in disappointment [11, 12]. The robust immune responses observed in mice could not be replicated in non-human primates (NHPs) or humans. One of the major reasons cited for this was the inefficiency of the delivery of the pDNA into the host's cells. This appeared to be less of an issue for small animal studies that often compensated for this by using very high (dose by body weight) doses and by forced cellular transfection through hydrodynamic pressure.

1.3. DNA-based Vaccination: The Delivery

Even though the excitement associated with DNA-based vaccination waned during the first few years of this century, investigators that remained in the field focused their attention on further defining pDNA's interaction with the innate immune system, how and what adjuvants could be used in combination, and maybe most importantly, understanding how the use of certain modalities could enhance the delivery and cellular uptake of large (several kbp's) pDNA molecules. Platforms developed to enhance *in vivo* pDNA delivery included ballistic devices, polymers, bacteria, sonoporation and electroporation [6, 13 - 19].

As mentioned above, EP has been successfully employed to assist in the delivery of nucleic acids into cells, both *in vitro* and *in vivo*. EP achieves this by inducing transient perturbation in the cell membrane and an electrical gradient that permits entry of large molecules, such as pDNA vaccines, into the cell. Studies have described an increase in tissue gene expression by 100-1000 fold when reporter

Sonophoresis: Therapeutical Uses and Devices

José Juan Escobar-Chávez*, Pablo Serrano Castañeda, Omar Rodrigo Guadarrama-Escobar, Alma Lidia Aguiñaga-Mireles, Miriam López-Cervantes, Clara Luisa Domínguez-Delgado and Jessica Martínez-Hernández

Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, México

Abstract: The administration of drugs in the skin using ultrasound is recognized like sonophoresis. The ultrasound is dating back to the fifties for high frequency (HF) and low frequency (LF). It has been investigated over the past two decades. Clearly, the use of ultrasound to drug delivery (DD) recently gained importance, thereby increasing patents and new commercial devices.

This chapter shows the important findings in sonophoresis. Particular attention is focused into therapeutical applications including transdermal drug delivery (TDD), gene therapy, sport medicine and sonophoretic devices.

Keywords: Physical enhancers, Skin, Sonolysis, Sonophoresis, Sonophoretic devices, Sport medicine, Ultrasound.

1. INTRODUCTION

Applications of ultrasound were used as an imaging technique. In the decade of the twenties, ultrasound (US) showed that could generate modification in human's

* **Corresponding author José Juan Escobar-Chávez:** Unidad de Investigación Multidisciplinaria. Laboratorio 12: “Sistemas Transdérmicos y Nanomateriales”, Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán–Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, CP. 54714, México; Tel: + (52 55).56.23.19.99; Fax: + (52 55). 56.15.70.77; E-mail: josejuanescobarchavez@gmail.com

organisms, thus began the US treatment [1].

The use of ultrasound in tissue generates heat thereof due to absorption of energy, allowing the use under different conditions. Recently it has been studied that the same benefit is obtained without thermal application by US.

US treatments could be divided as low and high frequency, LF covers the applications as phonophoresis, gene and physiotherapy, and last but not least important it can be used for bone healing.

The application of US has been used for many years in the medical field.

US have 3 different arrangement applications. These are shown in Table 1.

Table 1. Set of US conditions based on frequency (F) range.

Ultrasound types (frequency ultrasound)	Range of frequencies (KHz)
Low	20-100
Medium	0.7-3.0
High	3.0-10.0

Table 2. Principal applications of US.

<i>Relevant Applications of Ultrasound</i>
(i) For diagnosis in medicine.
(ii) For physical therapy (0.1- 15 MHz) the application of higher frequencies restricts the action to more superficial layers in to the skin.
(iii) In sport medicine. It can reduce healing times in fresh fractures or injuries in almost 30 -38% (<0.1 W/cm ²).
(iv) For transdermal, ocular and unguinal/transungual DD, ocular permeability enhance through changes in the structure of the cornea (20kHz).
(v) In surgery, practice patterns, traditional delegation of use and involving procedures (5-10 MgHz).
(vi) In gene therapy increases plasmid transfection through the formation of short pores in the plasma membrane.
(vii) For the treatment of tumors. US is used to treat a variety of solid tumors with the advantage that this technique have a fewer complications after treatment.

The principal medical applications of US are shown in Table 2. Initially US was

investigated for the treatment of skin conditions [2, 3] and swelling of joints [4]. Lately is of interest to use it for TDD [5] and gene therapy [6].

In recent years, reviews with important information on a lot of aspects of sonophoresis have been published [7 - 15]. This chapter displays a well-run view of therapeutic, pharmaceutical applications of US and sonophoretic devices. This Approach is justified because of the information available by US uses.

2. THE US

US is an energy that spreads [16,17]. Path propagation is parallel to oscillation direction as observed in Fig. (1).




Fig. (1). Representation of sound wave propagation.

The concentration of energy within a specific area in an US ray is called intensity (I). The intensity is decreasingly when US pass into the body, this is called attenuation. Tissue attenuation occurs for the absorption and sound force that are converted to warmth and scattered [13, 18] (Fig. 2).

Other experimental variables [17] that are important in sonophoresis are shown in Table 3.

Duty cycles are common at 10%, 25%, 50% or continuous application [19 - 28]. US is frequently used in pulsating as it lowers the effects of warming related by US. Various horn-to-skin spaces are utilized in sonophoresis studies, ranging from placing the US horn skin contact about 4 cm [28, 29]. Treatments vary over time,

Radiofrequency as Physical Approach for Transdermal Penetration Enhancement, Non-Surgical Skin Procedures, Orthopedics and Chronic Pain

Jennyfer Cázares Delgadillo*

R&I, L'Oreal, 188-200 rue Paul-Hochart, 94550 Chevilly-Larue, France

Abstract: This review provides a summary of studies on the use of radiofrequency to overcome the skin barrier in order to evaluate its therapeutic potential, primarily in the fields of drug delivery and gene therapy. Other applications in non-surgical dermatologic procedures, orthopedics and treatment of chronic pain are also addressed. Additionally, this chapter includes a description of common devices used in some of the fields described and information of risks, safety and cost of treatments in the area of medical skin procedures.

Keywords: Chronic pain, Dermatology, Drug delivery, Gene therapy, Non-contact, Non-invasive, Non-surgical, Orthopedics, Radiofrequency, Therapeutics.

1. INTRODUCTION

Radiofrequency (RF) is a versatile technology commonly employed to generate therapeutic intensities of heat in order to produce structural and biological responses. RF ablation methods were first introduced as a minimally-invasive procedure in the field of neurology, and it has been expanded to other domains to treat tumors in the lung, some types of ventricular arrhythmias, varicose veins,

* Corresponding author Jennyfer Cázares Delgadillo: R&I, L'Oreal, 188-200 rue Paul-Hochart, 94550 Chevilly-Larue, France; E-mail: jennyfer.cazares@gmail.com

endovenous ablation, treatment for Barret's esophagus, uterine fibroids, healing of bone tissue and skin lesions [1]. It is recently used as promising non-invasive strategy for transdermal penetration and gene delivery enhancement, orthopedics, sleep apnea and chronic pain [2 - 5]. The term non-invasive refers to non-surgical methods and does not involve penetrating the body as by incision or injection.

The principle mechanism of RF is electroconductive heating, also referred as ohmic heating or resistive heating. This term is defined as the passage of electrical current (either DC or alternating current) through a material which functions as an electrical resistance in which heat is generated.

One of the biggest challenges in drug delivery is the ability to transport the therapeutic agents into the body safely and reliably. Skin, the largest soft membrane tissue covering the body is an ideal target for certain treatments including gene therapy. However, the stratum corneum (SC), the outermost layer of the epidermis forms a barrier to protect underlying tissue, impeding the passage of therapeutic molecules. There are several penetration enhancement strategies that would increase the number of drugs available for transdermal administration without having safety issues. Vehicle-based drug which does not change the SC properties such as vesicles and particles [6], pro-drugs [7], and synergistic system [8, 9], or chemical penetration enhancers, representing a good strategy as absorption accelerants [10]. Another interesting approach is physical and electrical methods that temporarily diminish the barrier of the skin by accelerating the absorption of molecules to enhance either drug flux or gene expression [11]. Those may include iontophoresis [12, 13], electroporation [14], microneedles [15], laser techniques [16] and radiofrequency [2, 17, 18]. RF technology assists the percutaneous penetration of actives (including peptides and gens) by removal of the outermost layer of the skin by using an alternating electrical current preferably from 100 to 500 KHz. The flow of this current through the tissue produces ions to collide one another which results primarily in localized heat creating transitory micro-pathways across the SC and epidermis, increasing the passage of hydrophilic compounds across the skin. The risk of discomfort or painful sensation is minimal as the microchannels created do not reach ending nerves [19].

Non-contact RF is shown to be an effective alternative in the field of dermatology and cosmetics. It is called non-contact RF because the active electrode does not touch directly the tissue surface. Only few scientific data on the relevancy of this technique regarding its impact on structural changes of skin tissues has been communicated. Many clinical studies considering the RF procedures as safe, tolerable, of rapid recovery and effective for skin treatments have been carried out. However, such trials are commonly obtained from non-randomized and non-comparative data using subjective means of evaluation, showing modest results [20, 21].

Non-contact RF has also been employed in orthopedics as an effective tool for controlled heating of tissues (above physiological temperature) to generate structural and biological effects. Tendon diseases for instance represent an important (30%) proportion of rheumatologic consultations in day-to-day consultations [22]. RF energy works to shrink and tense ligaments and articular capsule tissue in a controlled manner [23]. Actually, hydrogen bonds of collagen molecules may break at supraphysiologic temperatures, which collapse the molecule allowing connective soft tissue to shrink. Some symptoms of tendinopathies coming from irritation of nociceptors may be treated by bipolar RF by inducing degeneration of nerve, and delay of newly developed sensitive afferent fibers into treated tissues [24]. RF energy applied above supraphysiologic temperatures may also induce an anticipated response, similar in time and nature of the wound healing responses of thermal and surgical damages, following a predictable sequence of events that contributes to inflammation [23].

This chapter presents experimental and clinical data of therapeutic applications of non-invasive RF to enhance primarily transdermal drug delivery. Furthermore, the effectiveness of this technique in cutaneous gene delivery, as well as in areas such as non-surgical dermatology, orthopedics and chronic pain is also discussed. To conclude, the description of devices used in the mentioned fields and the relationship between cost, risks and safety of different dermatological procedures is described.

Microneedles

Yunhua Gao*, Yuqin Qiu and Suohui Zhang

Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China

Abstract: Transdermal drug delivery is a well-accepted route of administration for therapeutical drugs. Skin is the largest area human body organ, however, the substantial barrier property of the skin stratum corneum limits practical value of transdermal route of drug administration. It has been proved that microneedle array devices can overcome the barrier characteristics of the stratum corneum and enhance the delivery of therapeutic medicines through skin. This chapter focuses on looking at the microneedle-mediated transdermal drug delivery for therapeutical applications. The definition of microneedles, enhancement mechanisms and devices in research or in the market are also depicted.

Keywords: Definition, Devices in research or in the market, Mechanisims of action, Microneedle, Therapeutical applications.

1. INTRODUCTION

Transdermal drug delivery (TDD) is convenient for the delivery of active pharmaceutical ingredients. The transdermal route offers some advantages compared with other noninvasive routes of drug delivery, such as the circumvention of first-pass hepatic metabolism, increased compliance and potential for controlled release. However, the clinical application of transdermal drug delivery has been limited because of the extremely low permeability of drugs through the stratum corneum [1].

* **Corresponding author Yunhua Gao:** Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China; Tel/Fax: 0086-10-82543581; E-mail: yhgao@mail.ipc.ac.cn

Microneedle array devices with sub-millimeter needle-shaped structures was expected to overcome obstacles of the outermost skin layer, the stratum corneum. The concept of microneedles, piercing through the stratum corneum and increasing markedly drug skin permeability without stimulating sensory nerve endings and causing pain was first put forward by Gerstel MS and Place VA in 1976 [2]. And Henry *et al.*, demonstrated the proof of the concept experimentally in 1998 for transdermal drug delivery [3]. Since then, hundreds of preclinical studies have been reported. Microneedle technology has shown great effectiveness in promoting the penetration of macromolecules, hydrophilic substances, vesicles and nanoparticles. Recently, numerous types of microneedles have been clinically examined across a range of applications, including drug and vaccine delivery. The aim of this chapter is to give an overall picture of the main features of microneedles used for transdermal and topical drug delivery. The definition of microneedles, enhancement mechanisms, therapeutical applications and devices in research or in the market are depicted.

2. DEFINITION OF MICRONEEDLES

Microneedles are a kind of drug delivery device for the use in the percutaneous administration of a drug for local therapy or systemic therapy. Microneedles can be defined as solid or hollow according to its structure. The device generally comprises a multiplicity of micron sized needles which are attached to a base support. The typical height is range from 100 to 1000 μm (*e.g.* Fig. 1). A variety of materials have been evaluated for the fabrication of microneedles, such as silicon, metal, ceramics and polymers [4, 5].




Fig. (1.1). A. Solid silicon microneedles, B. Solid metal microneedles (from author's lab).




Fig. (1.2). Hollow silicon microneedles. (A) A single microneedle, (B) the microneedle tip, and (C) a microneedle array (Reprinted with permission from [6]. Elsevier (2009)).




Fig. (1.3). Hollow microneedle used for intradermal infusion. Microneedles length (a) 0.5mm, (b) 0.75 mm, (c) 1 mm and (d) 4 mm, (e) Hypodermic needle (26-gauge). All images are obtained under bright field microscopy at the same magnification. (Reprinted with permission from [7]. Elsevier (2011)).

In addition, different terms have been reported in the literature base on the geometry or application of the needle, such as micropile [8], microstructure [9], microprojections [10, 11], micron sized lancets [12], microdevices [13], *etc* [14 - 18]. Despite of use of different terms, all these microneedles were for the same purpose, namely to pierce stratum corneum to form hydrophilic pathways by minimally invasive method without contacting the nerves of the skin to avoid bleeding or pain. Human volunteers have reported that a microneedle array having 5×10 arrays of $620 \mu\text{m}$ long stainless steel needles was not painful upon insertion [19]. Another study in 18 human volunteers reported that microneedle insertion

Nanocarrier Systems with the Use of Physical Enhancers

Roberto Diaz-Torres^{1,*}, Isabel Marlen Rodríguez-Cruz^{2,3}, Elizabeth García-García⁴, Clara Luisa Domínguez-Delgado⁵ and Patricia Ramirez-Noguera¹

¹ *Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Estado de México, México*

² *Hospital Regional de Alta Especialidad Zumpango. Unidad de Enseñanza e Investigación. Carretera Zumpango-Jilotzingo #400. Barrio de Santiago 2da Sección. Zumpango, Estado de México. C.P. 55600, México*

³ *Laboratorio de Investigación en Citogenética Básica del CBT Dr. Alfonso León de Garay. Calle Fresnos S/N, San Mateo, Tequixquiac, Estado de México C.P.55657, México*

⁴ *Psicofarma S.A. de C.V., Calz. de Tlalpan 4369, Col. Toriello Guerra, Distrito Federal. C.P. 14050, México*

⁵ *Unidad de Investigación Multidisciplinaria. Laboratorio 12: "Sistemas Transdérmicos y Nanomateriales". Facultad de Estudios Superiores Cuautitlán-Universidad Nacional Autónoma de México. Km 2.5 Carretera Cuautitlán-Teoloyucan, San Sebastián Xhala, Cuautitlán Izcalli, Estado de México, CP. 54714, México*

Abstract: At present, nanotechnology has acquired great importance. One of the fields where nanotechnology has been used with great success is medicine. This has allowed the emergence of a branch of nanotechnology called nanomedicine. Nanomedicine has been used by all known routes of administration (oral, intravenous, transdermal, *etc.*). Topical/transdermal route is one of the most used routes to administer formulated drugs in nanocarrier systems (nanoparticles, liposomes, dendrimer, transfersomes, nanoemulsion, *etc.*) in combination with the use of physical enhancers (microneedles, iontophoresis, sonophoresis, *etc.*). This route has great potential to deliver drugs, but the stratum corneum, which is the most external layer of the skin, confers properties of permeability to this organ.

* **Corresponding author Roberto Diaz-Torres:** Unidad de Investigación Multidisciplinaria, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Estado de México, México; Tel/Fax: +52 55 56231939; E-mail: diaztorres_r@hotmail.com

José Juan Escobar-Chávez (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

In order to modify the skin barrier properties and use the skin as a route to administer drugs into the body, some interesting strategies have been developed in last decades, such as the use of chemical and physical enhancers and even the combination of these enhancers with nanocarrier systems. For this reason, this chapter mainly emphasizes the applications of the 3 main physical enhancers (ultrasound, iontophoresis and microneedles) with nanocarriers for administering drugs by topical/transdermal routes, where they have been more widely used.

Keywords: Nanocarriers, Physical enhancers, Transdermal drug delivery.

1. INTRODUCTION

At the present time, nanotechnology has tremendously influenced all fields where it has been used. In the field of medicine has revolutionized many of the concepts existing up to date; for that reason, the emergence of a new hybrid concept between nanotechnology and medicine, is known as nanomedicine [1]. This new branch of medicine has changed the concept we had of treatment and diagnosis of diseases [2]. On this scale of nanometers, it is possible to treat a disease at the level of cellular organelles and adequately, control its progression. The drug path at the nanoscale is carried out by a modern version of a vehicle that protects the drug from action of the immune system, changes of pH, and it is made for the desired site of action. These so-called nanoscale vehicles are known as nanocarriers (Fig. 1).




Fig. (1). Schematic representation of an ideal nanocarrier.

2. DEFINITION AND GENERALITIES OF NANOCARRIER SYSTEMS

Nanocarriers are colloidal drug delivery system in the neighborhood of 1 to 1000 nm. These systems are very tiny and they are compared to some body structures [3]. Nanocarriers are nanosized particles and they are made of different macromolecules to be able to be administered by different routes. Nanocarriers can be administered *via* different the routes. The size of nanocarriers, let them be undetectable for the immune system; for that reason, they are the perfect tool to fight again a lot of illnesses and carry the drug directly in the target organ. This fact, helps to avoid side effects and increases the effectiveness of the drug [4 - 8].

The nanocarriers have become an interesting option to deliver drugs, gene therapy [9], for increasing the bioavailability of poorly soluble drugs [10] with low permeability or for percutaneous administration. Chemicals that were unlikely to be administered, now with nanocarriers may be used in therapeutic applications [11]. There are drugs that were not feasible to use as therapeutic agents due to their low bioavailability, and by the need of high concentrations to exert a pharmacological effect with the possibility of leading to toxic levels. But now by mean of nanocarriers their application is possible.

The nanocarriers can be made with a lot of substances, for example, polysaccharides [12], natural or synthetic polymers [13], lipids [14], proteins [15], amino acids [16] and inorganic compounds (Fig. 2). The use of different materials for nanocarriers makes these systems to have great physicochemical, pharmacological and toxicological properties. This variety of materials permits that nanocarriers can be loaded with a wide range of drugs with different physicochemical and pharmacological characteristics.

These nanostructures can be made to be very specific for the intended purpose; for example, it can be placed on the surface of these systems folic acid [17], since it is known, that many of cancers have an over expression of folate receptors. This strategy helps nanocarriers to link to the site of action and they will be joined to these receptors, making them much more targeted release of the drug directly to the tumor.

Therapeutic dose concepts used in traditional pharmacology, will change

Glossary

- Cavitation** = formation of vapour cavities in a medium upon ultrasound exposure.
- Dendrimers** = monodisperse populations those are structurally and chemically uniform. They allow conjugation with numerous functional groups due to the nature of their branches.
- Electroporation** = phenomenon in which cell membrane permeability to ions and macromolecules is increased by exposing the cell to short high electric field pulses.
- Gene delivery** = is a therapeutic technique, in which a functional gene is inserted into a patient's cells to correct a genetic defect or to provide the cells a new function.
- Iontophoresis** = consists of the application of a low density current and low voltage (typically 0.5 A/cm²) *via* an electrical circuit constituted by two drug reservoirs (anode and cathode) deposited on skin surface.
- Liposomes** = are hollow lipid bilayer structures that can transport hydrophilic drugs inside the core and hydrophobic drugs between the bilayer.
- Microneedles** = is a drug delivery device for use in the percutaneous administration of a drug for local therapy or systemic therapy.
- Nanoemulsions** = are isotropic dispersed systems of two non-miscible liquids, normally consisting of an oily system dispersed in an aqueous system (o/w nanoemulsion), or an aqueous system dispersed in an oily system but forming droplets or other oily phases of nanometric sizes (100 nm).
- Nanoparticles** = is a small object that behaves as a whole unit in terms of its transport and properties.
- Physical penetration enhancers** = Enhancement technologies that increase the passage of drugs throughout the skin.
- Radiofrequency** = is a versatile technology commonly used to generate therapeutic levels of heat by using various forms of alternating current.
- Reverse iontophoresis** = convenient non-invasive method for extracting substances through skin, allowing this way sampling body fluids to monitor them efficiently.
- Sonolysis** = therapy that involves administration of microbubbles with ultrasound, but without the administration of a thrombolytic drug.
- Sonophoresis** = absorption of ultrasonic energy that has been used with therapeutic intent in many conditions.
- Transcorneal iontophoresis** = delivery of a high concentration of drug to the anterior segment of the eye: cornea, ciliary body, aqueous humors and lens.
- Ultrasound** = a form of mechanical energy that is propagated from one point to another by the interaction between neighboring oscillating particles.

SUBJECT INDEX

A

Absolute bioavailability 165
 Acebutolol 238
 Acid 54, 113, 127, 179, 185, 228, 262, 277, 279, 290, 291
 (ATRA), All-trans retinoic 228
 amino 54, 262, 277, 279
 oleic 113, 127
 polylactic 179, 185, 290, 291
 Acne scars 192, 175
 moderate 175
 Acne vulgaris 174
 Acute ischemic stroke 120, 121
 Acyclovir 47
 Adipose tissue 119, 181, 183, 190
 Anaesthetics, local 45
 Ankylosing spondylitis 160, 161
 Antigen presenting cells (APCs) 115, 231
 Antitumor drugs 108
 Apoptotic index 182
 Application of mcRF 185, 186
 Applicator device 219, 220, 222
 Aqueous microchannels 10, 161, 162
 Aqueous pathways 237, 238
 Aqueous systems 270, 281
 Arrangement applications 102
 Atenolol 106, 113, 238

B

Barrier layer 38, 40
 Basal cell carcinoma 49
 Base polymer 219, 220
 Biological membranes 271, 276, 277, 279, 281, 286
 Biological tissues 153, 154
 Biomedical applications 11, 17
 Blood clots 105, 120, 121, 122, 123
 Blood flow 7, 122
 Blood glucose (BG) 52, 117, 223, 224, 287
 Blood glucose levels 52, 223, 287
 Botulinum toxin 46, 177
 Bovine serum albumin (BSA) 128, 129, 217, 218, 239, 240

Bursts 162, 166, 167, 170
 Buttock 182, 183

C

Caffeine 109, 110, 113, 189
 Calcein 109, 110, 113, 128, 129, 239, 240
 Cancers 10, 11, 50, 69, 76, 77, 78, 86, 87, 108, 168, 262, 265, 283, 295
 cervical 77, 87
 prostate 76, 78, 87
 Cancer therapy 19, 280, 295
 Cell death 8, 72, 115, 285
 Celectra intramuscular electroporation device followed by MVA-CMDR 80
 Cell membrane 5, 8, 70, 72, 73, 115, 154, 170, 181, 240, 263, 284
 Cells 4, 6, 9, 10, 11, 13, 17, 19, 69, 70, 72, 73, 84, 85, 86, 88, 89, 90, 114, 115, 158, 159, 220, 231, 240, 273, 278, 284, 295
 tumor 10
 Cervical intraepithelial neoplasia 76, 77
 Chemical enhancers 20, 47, 108, 109, 126, 127, 267, 296, 297
 Chemical penetration enhancers 112, 126, 127, 151
 Chemical promoters 104, 112, 126, 127, 131
 Chemotherapeutics 11, 50, 69
 Cholera toxin (CT) 234, 235
 Chondroitin sulfate (CS) 214, 219, 220
 Chronic hepatitis 79, 81, 83
 Circumferences, abdominal 12, 183
 Cisplatin 49
 Colloidal carriers 267
 Combination of ITP 238
 Combination of physical enhancers and nanocarriers 301
 Combination technologies 237
 Comfort pulse technology™ (CPT) 190
 Compounds 35, 40, 110, 216, 227, 239, 294
 skin-impermeable 227
 Concentrations of lidocaine 106
 Confocal laser scanning microscopy (CLSM) 17, 293
 Corneal permeability 110

Coronary vasculature 124
Corticosteroids 44, 108, 281, 288
Cost-effective skin permeation process 125
Critical micellar concentration (CMC) 271
Cryotherapy 173
CS microneedles 214
Current density 40, 41, 42, 45, 154, 163, 237
Cutaneous gene expression 171, 172
Cutaneous leishmaniasis (CL) 173
Cutaneous lymphoma 77

D

Days NTX delivery 228
Days post-microneedle application 228
Delivery 35, 39, 89, 91, 211, 213, 223, 224, 232, 236, 237, 238, 267, 271, 292
microneedle 223
passive 35, 39, 238
percutaneous 213, 267
subcutaneous 223, 224
transmembrane 271
vaccine 89, 91, 211, 232, 236, 237, 292
Delivery of MN-coated DNA vaccines 234
Delivery System 4, 12, 13, 51, 56, 75, 76, 77, 78, 79, 80, 81, 82, 83, 189, 218, 233, 241, 262
colloidal drug 12, 262
dermic drug 4
fluid 218
patient-controlled transdermal 51
prefillable 233
Delivery technique 37, 75
Delivery technology 91, 222
Dendrimers 4, 15, 260, 270, 271, 275, 276, 277, 281, 293, 300
Devices 9, 17, 51, 53, 54, 55, 56, 73, 74, 75, 84, 89, 90, 92, 101, 117, 119, 121, 124, 125, 128, 129, 152, 160, 161, 176, 183, 187, 188, 189, 190, 192, 193, 194, 198, 210, 211, 229, 230, 233, 240, 241, 242, 297, 298, 299, 300
automated microneedling 229, 230
contactless skin electrotransfer 74
dermal micro-needling 242
electrical active microneedle 240
microarray 298

microneedle array 210, 211
microneedle electroporation 240
penetrating 75
self-administrative 237
skin-penetrating 75
vivo electroporation 90
Devices in research 210, 211
Dexamethasone 10, 108, 109, 112, 288, 299
Dexamethasone iontophoresis 44
Dextrans 109, 110, 113, 165, 166, 219, 220, 221, 238
Dextrin 220, 221
Diabetes 12, 221, 224
Diclofenac 107, 160, 161, 162, 188, 213, 220, 228, 297
topical application of 228
Diclofenac plasma levels 162
Diffusivity 4, 7, 40, 128, 167
increased skin 128
Dimethyl sulfoxide 111, 112
Diphtheria toxin (DT) 235
Diseases 50, 114, 177, 261, 277, 279, 301
hereditary skin 50
Dissolving maltose microneedles and Iontophoresis 221
Dissolving maltose MN 219, 220, 222
Dissolving microneedles 165, 216, 217, 219, 223, 228, 238, 298
loaded 228
two-layered chondroitin 165
Dissolving microneedles loading insulin 223
DNA-based vaccine delivery and resulting immune responses 85
DNA delivery in skin 240
DNA-GTU vaccine administered 82
DNA vaccination 72, 84, 86, 91
DNA vaccine Delivered 76
DNA vaccine delivery 73
DNA vaccines 71, 82, 88, 90, 232, 234, 235
therapeutic 88, 90
Doxorubicin 16
Drug delivery device 211
Drug delivery system (DDS) 4, 7, 12, 15, 20, 110, 114, 187, 188, 262, 272, 274, 275, 292, 298, 301
Drug molecules 15, 218, 237, 239, 276
Drug nanocarriers systems 15
Drug release 10, 215, 299, 300

Drugs 4, 6, 10, 21, 22, 36, 38, 41, 44, 47, 48, 49, 52, 110, 117, 119, 120, 123, 128, 173, 177, 185, 189, 210, 214, 215, 216, 217, 218, 223, 237, 243, 262, 268, 269, 272, 274, 277, 280, 281, 282, 289, 293, 291, 299

amphiphilic 269

anti-cancer 21

anti-inflammatory 185

antimonial 173

antineoplastic 48

anti-Parkinsonian 52

antiretroviral 47

biotechnology 44

cancer 10

charged 38, 41

chemotherapeutic 277

coated 215, 243

dry 214

encapsulate 272

encapsulated 268

entrapped 21, 22

glaucoma 110

high molecular weight 117

injectable 223

insoluble 189

ionised 38

ionized 47, 128

lipophilic 216, 274, 280, 281, 282, 291

liquid 215

load 281

loaded 4

lytic 123

molecular weights 36

non-ionized 128

percutaneous 218

photosensitizer 280

potent 217

powdered 289

primary 44

received study 120

released 299

soluble 262

therapeutic 36

therapeutical 210

thrombolytic 119

topical 177

transdermal 6

transporting 277, 281

transporting anti-fungal 272

unionized 237

unionized polar 36

unstable 293

vasoconstrictor 49

Drugs 5-HT1 agonists 52

Drugs delivery 217

Drug skin permeability 211

Drugs pass membranes 263

Drug transport 10, 35, 36, 41, 126, 266

E

Ear permeation 35

Easy skin recovery 36

Ectodermal dysplasia 46

Efficient drug delivery systems 292

Electrical discharges 192

Electrical field, appropriate 73, 74

Electrical parameters 73, 91

Electric current treatment 35

Electric field 37, 39, 72, 75

Electrodes 8, 9, 37, 38, 40, 41, 43, 54, 75, 157, 161, 170, 187, 188, 190, 191, 192, 239, 286

49-microneedles 192

like-microneedles 191

Electrokinetic transungual system (ETS) 48

Electromotive drug delivery 35

Electroosmosis 5, 8, 38, 39, 40, 237, 238, 286, 287

Electroporation 9, 72, 240

in-skin 240

reversible 9, 72

Electroporation devices 73, 81

Electroporation-enhanced DNA-based vaccine delivery 86

Electroporation system 74, 84

Electroporation technique 5, 8

Electroosmosis 41

Endovascular System 122, 123

Energy 5, 7, 102, 103, 105, 114, 116, 121, 154, 157, 176, 178, 190, 192, 193, 194, 281

ultrasonic 5, 7

Energy modalities 193

Enhanced permeability and retention (EPR) 265, 295
Enhancement, skin conductivity 104
Enhancement mechanisms 210, 211
Enhancement of transdermal permeation of drugs 124
EP delivery 89, 90
EP delivery group 85, 86
EP delivery platform 68, 90
EP delivery tissue targets 74
EP devices 72, 74, 92
first generation 92
EP-enhanced delivery of DNA-based vaccines 75, 78
EP-enhanced delivery of DNA vaccines 71
EP-enhanced DNA-based vaccination protocols 73, 85, 86
EP-enhanced DNA-based vaccine delivery 74
Epidermal growth factor (EGF) 166, 167, 168
Epidermis 6, 9, 17, 75, 129, 151, 166, 167, 170, 172, 179, 181, 191, 229, 231, 232, 243, 292
Epinephrine 10, 45, 55
Epinephrine hydrochloride 49
EPRIME microneedle cartridges price 196
Erythema 21, 162, 176, 177, 197
Estradiol 15, 293
Ethosomes 270
Eye permeation 35

F

Fabrication, polymer microneedle 21
Fat deposits 182
FDA Approved 196, 197
FITC dextran 166, 167
Fluorescein 10, 106, 110, 111
Fluorescein isothiocyanate 238, 239
Fluorescent nanoparticles 171
5-fluorouracil 50, 108, 277
Food and drug administration (FDA) 11, 45, 51, 55, 56, 86, 120, 123, 125, 196, 197, 290

G

Gene delivery technique 170

Gene expression 75, 151, 170
Generalities of nanocarrier systems 262
Generation device associates monopolar delivery 190
Gene therapy 19, 72, 73, 101, 102, 103, 105, 108, 114, 150, 151, 168, 169, 197, 262, 273, 275, 280, 284, 297
Genetic material 115, 153, 170, 216, 284
Genexine 75, 77, 79
Giant unilamellar vesicles (GUV) 273
Glaucoma 50, 51, 106, 110
Glucose 53, 54, 108, 116, 125, 288
Glucose levels 52, 108, 116
Gold nanoparticles (GNPs) 280
Granisetron 160, 162, 163, 189

H

Hair follicles 6, 14, 37, 287, 295
Head and neck squamous cell carcinoma (HNSCCA) 76, 78, 87
Heat therapy 173, 174
Hemorrhagic Fever 82, 83
Hepatitis 83, 170, 216, 232, 234
Hepatitis C Virus (HCV) 74, 83, 89, 90
Herpes simplex virus (HSV) 170, 232, 235
HF sonophoresis 127
High frequency (HF) 7, 12, 101, 102, 153, 297
High intensity 19, 20, 109, 114
High intensity focused ultrasound (HIFU) 19, 20
Human immunodeficiency virus (HIV) 69, 74, 78, 79, 80, 81, 82, 83, 89, 90, 232, 236, 278
Human papillomavirus (HPV) 76, 77, 81, 88, 232
Human skin 11, 12, 16, 17, 112, 113, 171, 172, 230
excised 171, 172
treated 172
Human skin permeation 109
Hydrogels 111, 125, 294, 299
Hydrogel systems 216, 218
Hydrophilic drugs 161, 162, 163, 216, 227, 238, 270, 282
Hydrophilic microchannels 213, 215
Hydrophilic molecules 227, 238

Hydrophobic drugs 21, 216, 271
solubilize 271
Hydroxylapatite 179
Hyperhidrosis 10, 37, 45, 46, 56, 177, 178,
191
Hyperhidrosis disease severity scale (HDSS)
178
Hyperpigmentation 184, 229

I

Ichor medical systems incorporated 77, 79, 80
ImaRx Therapeutics 119, 120, 121
Immune responses 14, 68, 69, 74, 76, 79, 82,
83, 84, 85, 86, 87, 88, 89, 174, 231, 233,
234, 235
Immune system 13, 69, 89, 261, 262, 272,
278, 283, 301
Immune system attack 278, 279
Immunization 11, 19, 86, 90, 115, 189, 197,
234, 235, 292
Immunogenicity 77, 78, 79, 80, 81, 82, 88, 89,
91, 170, 233, 235
Immunotherapy 76, 77, 89
Impact patients self-esteem 180
Indomethacin 21, 107, 112, 127, 277, 293, 294
Infectious diseases 74, 78, 79, 81, 82, 86, 168
Influenza 69, 70, 80, 81, 82, 89, 170, 232, 233
Influenza subunit vaccine 233
Influenza vaccines 217, 232, 233, 241
Insertion polymeric microneedles 214
Insulin 11, 12, 52, 53, 108, 112, 116, 117, 216,
218, 221, 223, 224, 287, 289, 294
iontophoretic administration of 52
microneedle-delivered 224
Insulin delivery 52, 223, 224
microneedle-based 223
Intense pulse light (IPL) 194
Intermittent bursts 156
Interstitial fluids 213, 217, 230
Intracranial hemorrhages 120, 124
Intradermal 81, 82, 242
microneedle-based 224
Intradermal delivery 17, 215, 231, 233
microneedle-based 231
microneedle-based insulin 223
Intradermal drug delivery 217, 218

Intradermal vaccine delivery 241
Intramuscular administration 236, 292
Iontophoresis 10, 11, 16, 35, 43, 44, 45, 46,
47, 48, 49, 50, 51, 53, 54, 56, 127, 128,
294, 299
adopted 44
application of 35, 45, 48, 127, 128
applying 294
buccal 10, 50
cathodal 50
cisplatin 49
combination of 16, 53, 299
cutaneous 44
direct 43
low-voltage 128
mock 16
ocular 10, 50
passive drug administration 45
pilocarpine 46
reverse 43, 53, 54
transcorneal 50
transdermal 48, 56
transdermic 11
transscleral 51
ungual 47
Iontophoresis 5, 38, 39, 43, 44, 46, 52, 56,
292, 295, 299
and nanocarriers 292, 299
application transport 39
delivery 52
device 287
for Systemic Delivery 51
of anaesthetics 44
of human insulin 52
of tap water 46
process 43
systems 56
technique 38, 44
treatment 295
uses 5, 46
Iontophoretic 16, 35, 37, 40, 47, 49, 51, 52,
54, 55, 56, 299
application 16, 40
delivery 40, 47
devices 35, 37, 49, 51, 52, 54, 55, 56, 299
systems 56, 299

J

Jelectromigration 39
Jelectrosmosis 39
Jiontophoresis 39

K

Ketoprofen 107, 112, 274, 290
Ketoprofen gel 107
Ketorolac tromethamine (KT) 107, 112

L

Langerhans cells (LCs) 6, 115, 169, 231
Large multilamellar vesicles (LMV) 273
Large unilamellar vesicles (LUV) 273
LF and HF US for testosterone skin penetration 109
LF sonophoresis 107, 127, 128
LF sonophoresis and iontophoresis 127
Lidocaine 10, 37, 45, 55, 106, 107, 111, 126, 191, 221, 225, 226, 288
Lidocaine delivery 226
Lidocaine iontophoresis 45
Lidocaine skin penetration 106, 107
Lidosite, lidocaine iontophoretic device 45
Lipid base delivery systems 22
Lipid globules 269
Lipid microparticles 17, 18, 109
Lipid nanoparticles 267, 279, 293
Lipophilicity 36, 213, 238
Liposomes 4, 15, 17, 19, 22, 127, 260, 266, 267, 270, 271, 272, 273, 274, 280, 281, 282, 283, 290, 293, 295, 297, 299, 300
combination of 290, 295
neutral 273
ultra-flexible 282, 290
Local skin reactions 237
Low molecular weight heparin (LMWH) 221
Low voltage pulses 10

M

Magnetic Nanoparticles (MNPs) 280
Male wistar hannover 219, 220
Malignant melanoma 16, 76

Medical device development field 92
Medical devices 55, 196, 243
Medical solutions 123
Medical waste 215, 216
Medicine 8, 9, 12, 76, 78, 101, 102, 116, 131, 260, 261, 285, 286
sports 101, 102, 116, 131, 285, 286
Medium-sized unilamellar vesicles (MUV) 273
Melanin 184, 299
Melanoma 19, 74, 77, 78, 86, 168
Melanoma DNA vaccine delivered by electroporation 77
Melasma 108, 184
Metallic microneedles 243
Methotrexate 49, 221
Methyl nicotinate 109, 113
Micelles 4, 15, 130, 267, 271, 281, 282, 295
polymeric 282
Microchannels, microneedle-induced 52
Microfluidics components 215, 216
Microneedle administration 224, 227
Microneedle application 213
Microneedle arrays 128, 191, 212, 213, 217, 218, 219, 225, 226
cm2 titanium 225
solid silicon 219, 226
Microneedle array treatment, following 227
Microneedle-based drug delivery 223
Microneedle-based transdermal products 242
Microneedle design 215, 216, 223
types 223
Microneedle electrode array 240
Microneedle-injected sites 226
Microneedle insertion 17, 212
Microneedle insulin delivery 224
Microneedle matrix materials 217
Microneedle patches 229, 236
acid-loaded dissolving 229
dissolvable 236
loaded dissolving 229
Microneedle removal 213
Microneedles 18, 129, 193, 212, 214, 215, 217, 225, 226, 230, 240, 241, 242, 298
coated 215, 217, 225, 226, 230, 241
dissolvable 217, 242
empty 129
hollow 500- μ m 226

hollow conductive 240
insulated gold-coated 193
maltose 214
showed 18
single 212, 298
Microneedles and electroporation 130, 240
Microneedles and iontophoresis 237, 266
Microneedles dissolves 216
Microneedles designs 214, 215
Microneedles devices 17, 298
Microneedles dimensions 192
Microneedles form 298
Microneedles formulation 242
Microneedles length 212
Microneedles patch 229
Microneedles penetration depth 175
Microneedless 36
Microneedles technology 241
Microneedles tip 9
Microneedle technology 211, 229, 242, 243
Microneedle tips 212, 217
Microneedle treatment 228
Microneedle withdrawm 215
Molecules, lipophilic 238, 282
MR-guided focused US (MRgFUS) 19
Multifunctional nanocarriers, pharmaceutical 264
Multivesicular vesicles (MVV) 273
Muscle tissue 73, 74, 231, 300

N

6- β -Naltrexol 227
Naltrexone 222, 227, 228
Nanocapsules 4, 268, 278
Nanocarrier drug delivery systems 12
Nanocarriers 13, 22, 130, 261, 262, 263, 264, 265, 267, 268, 271, 290, 291, 292, 293, 294, 295, 296, 298, 299, 300, 301
combination of 291, 292, 295, 300
penetration of 296, 300
permeability of 295, 301
transmembrane 296
Nanocarriers systems 12, 19, 130, 268
Nanocarrier systems toxicity 14
Nanoemulsions 4, 15, 20, 260, 270, 271, 281
Nanomedicine 4, 260, 261, 295

Nanoparticles 4, 8, 12, 13, 14, 15, 16, 17, 18, 130, 171, 211, 216, 260, 265, 267, 268, 269, 271, 277, 278, 279, 280, 281, 282, 283, 289, 290, 291, 292, 293, 294, 295, 296, 298, 299, 300
administration of 292, 298
combination of 16, 296
fluorescent semiconductor 269, 282
gold 280
inorganic 267, 269
interaction of 265, 268, 279
liposome 130
magnetic 280
permeability of 291, 296
polymeric 268, 279, 280, 281, 293, 294, 295, 299
rigid 296
topical 171
Nanoparticles devices 298
Nanoparticle system 21
Nanopharmaceutics 4
Nanospheres 4, 268, 278
Nanostructured lipid carriers (NLCs) 279, 291
Nanosystems definition 268, 269, 270, 271
Nanovesicles 294
Neutral drugs 293
Niosomes 14, 21, 266, 270, 282, 299
Non-human primates (NHPs) 70, 71, 85
Non-invasive delivery of drugs 270
Non-invasive pulsed RF 187
Non-steroidal drugs 107
Non-surgical body contouring cellulite wrinkle skin tightening 196
Non-thermal effects 155
Non-viral agents 115

O

Ocular drug delivery 18, 19, 106, 110, 230
Ocular iontophoresis delivery 50
Oleic acid (OA) 113, 126, 127
Oligolamellar vesicles (OLV) 273
Oligonucleotides 12, 36, 109, 213, 216, 287, 289
OncoSec medical incorporated 76, 77, 78
Oncosec medical system™ (OMS) 76, 77, 78
Onychomycosis 48, 110, 113, 114

treatment of 110, 114
Orthopedics 150, 151, 152, 184
Osteoporosis 15, 189, 225, 243

P

Painkillers and drugs for inflammation 107
Parathyroid hormone (PTH) 189, 217, 224, 225, 241, 242
Passage of pDNA 72
Patch, coated titanium MN array 219, 220, 222
PDNA delivery 68, 69, 71, 72, 73, 85
Permeation of non-steroidal drugs for inflammation 107
Permission of AC sintov 162, 163
Peyronie's disease 44
Pharmaco-dynamic (PD) 189, 223
Phenytoin 54
Phonophoresis 102, 109, 110
Phospholipids 270, 271, 274, 282
Physical permeation enhancement 35
Physiological variations 40, 41
Plasma levels 51, 54, 105, 162, 163, 165
Plasmid DNA 69, 171, 172, 216, 217
Plasmids 84, 235, 284
Poly electrolyte multilayer (PEM) 292
Polyethylene glycol 265
Polymeric microneedles 214, 289, 291
drug-loaded 214
Polymer microneedles 213, 215, 225
non-dissolving 225
Polymers 70, 211, 215, 216, 217, 220, 265, 267, 268, 269, 273, 274, 276, 279, 281, 282, 289, 290
biodegradable 215, 279
crosslinked 216, 217
linear 276
Poly vinyl alcohol (PVA) 294
Post-menopausal women 225
Primary axillary hyperhidrosis (PAH) 178
Product, drug-device combination 54, 55, 56
Propylene glycol 20
Prostate specific antigen (PSA) 87
Protective antigens 235, 236
Protein drugs, macromolecular 18
Psoriasis 19, 49, 291

Q

Quantum dots (QDs) 15, 19, 22, 111, 230, 269, 282, 283, 296
Quercetin 17, 18

R

Rabbit cornea 110, 113
Radiesse 185
Radiofrequency 178
bipolar fractional microneedling 178
fractionated microneedle 178
Radio frequency ablation 171, 172
Radiofrequency ablation 5, 9, 11
Reduction of fluctuation in plasma level of drugs 105
Regeneration, skin cell 229
Regional blood flow 40, 41
Regions 13, 14, 110, 159, 279
alveolar 13, 14
nasopharyngeal 14
tracheobronchial 14
transport skin 110
Release drugs 20, 288
Renal syndrome 82, 83
Reservoir, drug-loaded 214, 215
Resistance 37
current application skin 37
current cessation skin 37
Restylane 185
Reticuloendothelial systems 265, 273
Retinyl retinoate 223, 228, 229
RF devices, monopolar 179, 182
RF energy 152, 153, 154, 158, 164, 179, 181, 190, 191, 192, 193, 194, 195, 196
bipolar 193
RF instrument 196, 197
RF microporation 167, 168
RF treatments 165, 174, 175, 177, 179, 180, 182, 185
serial microneedling fractional 175
Rheumatoid arthritis 49, 89, 160
Robust immune responses 69, 70, 89

S

- Sebaceous glands 6, 287
- Seborrheic keratosis (SK) 228
- SEP device, non-invasive 75, 84
- Showed microneedles aid 226
- Silicon microneedles 211, 214, 230, 239, 242
- long hollow 239
- solid 211, 242
- Single hollow microneedles 18, 221, 241
- Skin 4, 5, 6, 7, 8, 9, 11, 16, 20, 21, 41, 45, 48, 57, 74, 103, 104, 109, 110, 124, 125, 126, 127, 151, 152, 159, 161, 162, 163, 166, 167, 173, 175, 176, 178, 179, 180, 181, 182, 183, 184, 188, 189, 191, 192, 195, 196, 213, 216, 227, 228, 229, 230, 231, 232, 233, 240, 242, 273, 277, 290, 291, 292, 295, 296, 297, 300
- aging 189
- appendages 6
- blood flow 45
- brightness 180
- cancer 20, 48, 230, 277
 - non-melanoma 11
- cells 16, 74, 291
 - main immunological 231
- components disintegrate 292
- conditions 103, 180, 195, 196, 229
- damage 41, 295
 - irreversible 195
- defence, extra 109
- deformation 9
- electroporation 240
- immunization 233
- impedance 188
- irradiation 295
- irritancy 20
- irritation 227, 297
- irritation study 228
- keratinocytes 231
- laxity 178, 179, 180, 196
- moderate facial 179
- laxity correction 180
- lesions 151
- localized hypo-pigmented 173
- minimal 159
- lipids 126
 - microchanneling 161, 162, 163
 - penetration 11, 110, 126, 127, 176, 213
 - increasing digoxin 109
 - permeability 4, 5, 7, 20, 57, 104, 124, 125, 166, 240, 296, 297
 - permeation 110, 127, 162, 290
 - permeation system 124
 - phototypes I-IV 179
 - pigmentation 184
 - pretreatment 162, 227, 242
 - problems 229
 - rejuvenation 11, 300
 - renewal system 196
 - sensitivity 195
 - surface 8, 21, 181, 183, 192, 213
 - surface roughness and dermal density 175
 - temperature 184, 191
 - texture 176
 - improvements of 179, 180
 - thermal imaging 180
 - thickness 167
 - tightening 178
 - tissues 152, 182, 216
 - deeper 240
 - types, atrophic acne scars Fitzpatrick 176
 - vaccination 232
 - visiometer SV 229
 - unilamellar vesicles (SUV) 273
- Sodium fluoride iontophoresis 47
- Sodium lauryl sulfate 112, 127, 296
- Solid lipid nanoparticles (SLNs) 16, 266, 269, 279, 280, 291, 293, 294
- Solid metal 211, 219, 220, 221
 - microneedles 211
 - MN 219, 220, 221
- Solid microneedle-assisted delivery 216
- Solid microneedles 214, 215, 216, 219, 221, 224, 225, 227, 230, 240, 242, 243, 289, 290, 292
- long 240
- Solid microneedles and dissolving
 - microneedles loading insulin 223
- Solid stainless microneedle arrays and iontophoresis 221
- Solid stainless steel microneedle 219, 220, 222
- Solid stainless steel MN 221, 222
- Solid water-insoluble microneedles 217

- SoluviaTM for intradermal vaccine delivery 241
SoluviaTM microneedle delivery system 241
Sonophoresis, disadvantages of 104, 105
Sonophoresis and electrophoresis tetracycline application 108
Sonophoresis and electrophoresis tetracycline application in rabbits 108
Sonophoresis devices 116
Sonophoresis-microneedles 130
Sonophoretic device 101, 103, 116, 119
Squamous cell carcinoma 77, 78
Stereomicroscopy 172
Stratum corneum (SC) 3, 6, 20, 37, 52, 54, 104, 110, 125, 126, 127, 151, 159, 164, 167, 169, 187, 188, 192, 210, 211, 213, 218, 224, 226, 228, 260, 266, 267, 289, 290, 291, 292, 296, 300, 301
turnover (SCT) 228
Sumatriptan 41, 51, 55
Superoxide dismutase 295
Suppurated wounds 111
Surface devices 74
Surface EP (SEP) 75
Sweat glands 6, 37, 46, 177, 178
Swelling microneedles 214, 216, 217, 218
- T**
- Terbinafine 48
Teriparatide 225
Testosterone 109, 113, 165, 297
Testosterone-cyclodextrin 165, 166
Testosterone skin penetration 109
Theoretical basis of iontophoresis 37
Therapeutic agents 12, 115, 151, 218, 262, 264, 266, 278
Therapeutical applications 101, 210, 211 potential 22
Therapeutical applications of iontophoresis 44
Therapeutic applications 4, 10, 14, 104, 152, 159, 218, 262, 267, 300
Therapeutic molecules 4, 20, 151, 243
Therapy 47, 53, 90, 115, 159, 173, 174, 175, 182, 229, 284, 286, 292, 295, 296, 301
fractional RF microneedle 175
Thermal injury zones (TIZs) 12
Thickness, skinfold 182
Thrombosis 300
Thrombus 122, 123, 285
Tissue volume, adipose 180, 183
Titanium microneedles 217, 225
coated 217
Topical transdermal drug delivery 111, 112, 113
Topical/transdermal routes 131, 260, 261
Toxicity of nanocarrier system 14
Transdermal absorption 35, 53
Transdermal administration 4, 35, 53, 151, 287, 289, 295
Transdermal delivery (TD) 4, 9, 108, 126, 161, 162, 163, 165, 166, 189, 197, 218, 227, 230, 231, 237, 238, 239, 243, 266, 275, 295, 298
techniques 231
Transdermal drug delivery 7, 210
microneedle-mediated 210
systemic 7
Transdermal drug delivery (TDD) 4, 10, 11, 19, 101, 103, 106, 107, 108, 109, 110, 111, 117, 128, 152, 159, 163, 188, 190, 210, 211, 227, 237, 261, 293
Transdermal flux 11, 41, 42, 49, 238
Transdermal iontophoretic administration 52
Transdermal microneedle system 225
Transdermal RF drug delivery systems 187
Transdermal route 104, 116, 210
Transmembrane drug delivery 279, 281
Transport 5, 6, 8, 12, 40, 41, 47, 54, 107, 151, 187, 266, 267, 271, 274, 276, 277, 279, 283, 286, 287, 293, 299
iontophoretic 40, 41
Transport drugs 267, 277, 281, 283, 293, 299
Triamcinolone 109
Triclosan 15, 16, 21
deposition of 15, 16
TriGrid intramuscular delivery system 91
- U**
- Ultrasound and nanocarriers 295, 299, 300
Ultrasound application 21, 284
Ultrasound delivery of drug 130
Ultrasound devices 300

Ultrasound energy 7, 8
Ultrasound frequency 7
Ultrasound gene therapy 114
Ultrasound therapeutical applications 106
Ultrasound therapies 284, 297
Ultrasound transmitter 129
UVB irradiation 167, 168
UVB radiation 167
UV-irradiated skin 168

V

Vaccines 11, 69, 86, 88, 90, 91, 131, 213, 215,
216, 217, 232, 233, 234, 235, 236, 237,
242, 243, 275, 292
bacterial 235
polio 236

Vesicles, lamellar 270
ViaDerm™ drug delivery system 188
Viral clearance 88
Virus 69, 70, 88, 232, 233, 235
inactivated 69, 232, 233
Viruses, inactivated 232, 234
Virus like particles (VLPs) 232, 233
Visual analog scale (VAS) 84, 226

W

Whole-body vibration (WBV) 182
Wound healing responses 152, 185
Wrinkle formation 167, 168
Wrinkle treatment and skin tightening 196



José Juan Escobar-Chávez

Dr. Escobar-Chávez (Doctor of Chemical Sciences, University of Mexico, Mexico) is a professor at the Faculty of Chemistry and Pharmacy; University of Mexico. He joined the faculty in 1998. He has completed two postdoctoral researches with one year in each of them, one in abroad at the University of Valencia, Spain, in the Department of Pharmacy and Pharmaceutical Technology and the other at national level in Universidad Nacional Autónoma Metropolitana-Xochimilco in the Department of Biological Systems. He also made a doctoral stay at the University of Geneva, Switzerland, at "Centre de Recherche et d'Enseignement Interuniversitaire, Pharmapetides".

His research interests are in the Topical and Transdermal delivery of drugs and include the use of the tape stripping technique to quantify the pass of drugs, the use of TEWL and ATR/FTIR to show the changes of skin as a result of the use of chemical enhancers, the use of physical enhancers as iontophoresis, sonophoresis, solid and polymeric biodegradable microneedles and electroporation in the administration of transdermal drugs. Development and characterization of mucosal and ocular delivery systems and application of nanotechnology in transdermal drug delivery are others major research interests. He is author of 10 book chapters. He also is editor of the book "Current Technologies to Increase the transdermal delivery of drugs" from Bentham Science Publishers. He has 20 publications in indexed journals of high international impact in the area of Pharmacy and Pharmaceutical Technology. He has two patents of transdermal technological developments. He won the 2014 CANIFARMA prize awarded by the National Chamber of Pharmaceutical Industry in Mexico. He has been reviewer of many recognized journal of Pharmacy, Pharmaceutical technology and Dermatology. He teaches analytical chemistry, biopharmacy, analysis of drugs, and pharmaceutical technology at FES Cuautitlán-UNAM and he is involved in pharmacy curriculum development.